Back to results
US 10,501,728 B2Granted
Engineered nucleic-acid targeting nucleic acids
AssigneeCaribou Biosciences, Inc.
InventorsPaul Daniel Donohoue, Andrew Paul May
Life of this patent
Estimating the term…
Abstract
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Claims9
An engineered CRISPR Class 2 cross-type-nucleic-acid targeting nucleic acid (“CRISPR Class 2 cross-type-NATNA”), comprising:
- a first CRISPR Type II Cas9-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a spacer element complementary to a first nucleic acid target sequence (“first Cas9-NATNA”);
- a second CRISPR Type II Cas9-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a tracr element (“second Cas9-NATNA”) and a first linker element, having a 5′ end and a 3′ end, wherein the 3′ end of the first linker element is covalently connected at the 5′ end of the second Cas9-NATNA;
- a first CRISPR Type V Cpf1-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a spacer element complementary to a second nucleic acid target sequence (“first Cpf1-NATNA”), wherein the 3′ end is covalently connected with the 5′ end of the first linker element;
- and
- a second linker element, having a 5′ and a 3′ end, wherein the second linker element is covalently connected at the 5′ end of the first Cas9-NATNA or at the 3′ end of the first Cas9-NATNA or at the 3′ end of the second Cas9-NATNA.
2 more elements
Dependencies are inferred from the claim text.